The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.
Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.
This trial was terminated before completion. Termination can indicate safety signals, futility findings, or business/regulatory decisions by the sponsor.
Moderna Inc (MRNA) is the sponsoring company for this trial. BiotechSign currently grades this company C (59/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.